Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation: a Single-arm, Single-center, Exploratory Trial

NCT06546280 is registered in ClinicalTrials.gov with Zhujiang Hospital as lead sponsor.

NCT NCT06546280
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06546280 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation: a Single-arm, Single-center, Exploratory Trial
Lead sponsor
Zhujiang Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 26, 2024
Completion date
September 1, 2026
Enrollment
38 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma